Top Markets
Coin of the day
Scandion Oncology A/S Scandion Oncology A/S

Scandion Oncology A/S

SCOL
Rang in Aktien #40631
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S... Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Aktienkurs
$0.00045794
Zuletzt synchronisiert: 2025-07-11
Marktkapitalisierung
$107.51K
Veränderung (1 Tag)
-36.01%
Veränderung (1 Jahr)
0.00%
Land
DK
Handel Scandion Oncology A/S (SCOL)

Kategorie

Kursverlauf für Scandion Oncology A/S (SCOL)
Höchster Schlusskurs: $0.00 am 2025-07-01

Niedrigster Schlusskurs: $0.74 am 2018-11-01
Kursverlauf der Aktie von Scandion Oncology A/S von 2018 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2025 -92.13%
2024 -96.87%
2023 -14.41%
2022 -80.44%
2021 -42.28%
2020 127.83%
2019 80.43%
2018 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE